Roivant Sciences Stock Stages Tuesday Comeback—Here’s Why Traders Are Biting

Roivant Sciences shares clawed back losses in a Tuesday rally that left Wall Street shrugging—because biotech volatility is basically crypto with lab coats.

The Bounce Breakdown

No dramatic FDA approval or short squeeze fueled this rebound. Just the usual sector rotation where money sloshes between overhyped pipelines like gamblers at a roulette table.

The Bigger Picture

Speculators keep treating drug development stocks like meme coins—pumping on rumor phases, dumping before actual data. Roivant’s 52-week chart? Basically an altcoin trading pair against hopium.

One analyst muttered about 'undervalued assets' while discreetly closing their long position. Classic.

Boosting the biotech

Tuesday's raiser was Leerink Partners prognosticator David Risinger. Well before market open, he added $1 to his Roivant price target for a new level of $18 per share. In doing so, he maintained his recommendation of outperform (read: buy) on the company's stock.

Image source: Getty Images.

According to reports, Risinger's adjustment is based on a change in his forecast for the biotech company's share count. The analyst based this on management's statements about its share repurchase program, which is expected to shave the tally for shares outstanding.

As for Roivant's operations, the pundit waxed bullish on the eventual outcome of the company's phase 3 clinical trial of brepocitinib in the treatment of dermatomyositis, a rare inflammatory disease that can affect the muscles and the skin. He's anticipating a readout of the trial to be published in the second half of this year.

A first quarter to forget

Risinger's continued bullishness on Roivant was a morale-booster for the market, which had traded out of the company's shares after Monday's fiscal first quarter of 2026 earnings release. The company reported significantly lower revenue compared to the same period of 2025, and it flipped to a net loss on the bottom line.